European Medicines Agency Grants PRIME, Advanced Therapy Medicinal Product Designations to Janssen RPGR Gene Therapy for X-Linked Retinitis Pigmentosa
March 03, 2020
March 03, 2020
RARITAN, New Jersey, March 3 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, issued the following news release:
* * *
- Only RPGR gene therapy program to receive PRIME designation
- Designations will accelerate the regulatory review timeline of this potential gene therapy for European patients living with X-linked retinitis pigmentosa
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson an . . .
* * *
- Only RPGR gene therapy program to receive PRIME designation
- Designations will accelerate the regulatory review timeline of this potential gene therapy for European patients living with X-linked retinitis pigmentosa
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson an . . .